Abbvie Inc.

Jianwei Wu

Yi Gao

Geoff G Zhang

Yi Shi

Ping Gao

Yanxia Li

Rudolf Schroeder

Bernd Liepold

Nancy E Sever

Ulrich Westedt

Mirko Pauli

Peter Hölig

Bryan K Erickson

Justin S Lafountaine

Renato Koenig

Madlen Thiel

Tina Jung

Yi Goa

Brent D Sinclair

Simon Kullmann

Gerd Woehrle

Tanja Heitermann

The present disclosure relates to pharmaceutical compositions of pyrimidinedione derivative compounds and methods of preparing and uses thereof. The disclosure also relates to methods of enhancing bioavailability of pyrimidinedione derivative compounds in pharmaceutical compositions administered to a subject and methods of reducing the amount of a pyrimidinedione derivative compound in a pharmaceutical composition while achieving the same bioavailability in a subject.

Formulations of pyrimidinedione derivative compounds

The present invention features solid compositions comprising Compound I, Ior I, or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound I, Ior I, or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

Solid compositions

The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

Growing community of inventors

Potomac, MD, United States of America

Jianwei Wu